Background {#Sec1}
==========

Radiotherapy plays a major role in the management of many types of cancer. There are challenges regarding why tumors are resistant to radiation. Although preoperative concurrent chemoradiotherapy (CCRT) or short-course radiotherapy \[[@CR1]\] are the main treatments for rectal cancer, some patients choose surgery as their initial therapy for personal reasons. However, the influence of the tumor marker carcinoembryonic antigen (CEA) on the prognoses is not clear in patients who undergo post-operative radiotherapy (PORT). Our prior study first noted that pretreatment serum CEA levels are associated with local recurrence (LR) after radiotherapy for cervical cancer \[[@CR2]\]. Therefore, we were interested in the role of CEA in a different cancer. Rectal cancer was a good candidate because radiotherapy is usually applied, and elevated serum CEA levels are noted in rectal cancer patients.

CEA is a complex glycoprotein with different glycosylations that cause different molecular weights between normal and cancer cells. The activation of glycosylphosphatidylinositol phospholipase D can release membrane-bound CEA and result in shedding \[[@CR3]\]. Genetic manipulation of CEA in cancer cell lines promotes CEA release from cell membrane \[[@CR4]--[@CR6]\]. Upon its secretion, CEA promotes colorectal cancer cell metastasis especially to the liver. Kupffer cells are specialized macrophages and enhance liver metastasis \[[@CR7]\] through their CEA receptors \[[@CR8]\]. Tumor-associated macrophages (TAMs) are heterogeneous in human malignant tumors. TAMs are nearly always associated with poor prognoses. However, the TAMs of colorectal cancer are correlated with favorable prognoses \[[@CR9]\]. Based on the literature and our previous studies, we hypothesized that cancer cells secrete CEA to modulate macrophage differentiation and subsequently increase the radioresistance of cancer cells. The specific aims of this study were to examine whether CEA enhances radioresistance in patients with rectal cancer and assess the involvement of CEA-stimulated macrophages in radioresistance.

Methods {#Sec2}
=======

Patient collection {#Sec3}
------------------

Patients with histologically proven pT3--4 or N1--2 adenocarcinomas of the rectum who were treated with curative-intent surgery and post-operative radiotherapy were reviewed in this study. Patients who did not receive the planned dose (45--55 Gy) of radiotherapy or exhibited distant metastasis were excluded from the study. Between July 1997 and January 2008, 104 patients were included in the study. The characteristics of patients are presented in Table [1](#Tab1){ref-type="table"}. This study was approved by the Institutional Review Board of our hospital (99-3189B).Table 1Patient characteristics (*n* = 104)ParametersNo. (%) or Mean ± SEMAge (years)55.9 ± 11.5Stage II20 (19.2%) III84 (80.8%)T stage T24 (3.8%) T353 (51.0%) T447(45.2%)N stage36 (19.1%) N020 (19.2%) N159 (56.7%) N225 (24.0%)APR No61 (58.7%) Yes43 (41.3%)Anal verge (cm) ≤559 (56.7%) 6--1034 (32.7%)  \> 1011 (10.6%)Pretreatment CEA level (ng/mL)17.3 ± 3.7  \< 556 (58.3%) 5--1018 (17.3%) ≥ 1030 (28.8%)EBRT dose (Gy) 45--50.46 (5.8%) 52.2--54.698 (94.2%)

Radiation therapy {#Sec4}
-----------------

In general, the upper margin of the pelvic irradiation was delivered with 10- or 15-MV photons through 3-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiotherapy (IMRT) techniques. Typically, the upper margin was 1.5 cm above the level of the sacral promontory. The posterior margin was 1.5--2 cm behind the anterior bony sacral margin. The dose was 45--55 Gy in 25 to 28 fractions that were administered within 5--6 weeks. Typically, the patients received 5-fluorouracil (5-FU)-based chemotherapy concurrently with the radiotherapy.

Follow-up and statistics {#Sec5}
------------------------

After the completion of the radiotherapy, follow-ups of the patients were performed and included physical examinations, laboratory tests, chest X-rays, colonoscopies, and computed tomography (CT) scans. Local recurrence (LR) and distant metastasis (DM) were confirmed by biopsy, physical examination, or imaging diagnosis. The overall survival (OS), LR, and DM rates were calculated via the Kaplan-Meier method, and the differences were examined with the log rank test. The interval to the last follow-up was defined by the last administration of radiotherapy. Multivariate analysis was performed using the Cox proportional hazard model with a forward stepwise procedure for OS, LR, and DM. The relative risks of these variables are represented by the hazard ratios (HRs) with the 95% confidence intervals (CIs). All variables, including age (\< 57 and ≥57 years), stage, CEA level (\< 10 and ≥10 ng/mL), tumor location, and operation, were treated as categorical data. The statistics were performed on a personal computer using the SPSS 17.0 software (SPSS Inc., Chicago, IL) for MS Windows®.

Cell culture {#Sec6}
------------

THP-1 (TIB-202), SW48 (CCL-231), SW620 (CCL-227), DLD-1 (CCL-221), LS1034 (CRL-2158), HCT116 (CCL-247), LS174T (CL-188), LS180 (CL-187), and Caco2 (HTB-37) cells were purchased from the American Type Culture Collection. The cells were grown in the suggested media with 4.5 g/l glucose and supplemented with 10% fetal bovine serum (Gibco Life Technologies, Grand Island, NY, USA) and antibiotics at 37°C in 5% CO~2~. The media were changed every 3 days.

Macrophage differentiation {#Sec7}
--------------------------

Harvested differentiated THP-1 cells were seeded at a density of 2×10^6^ cells in 25 T flasks. The THP-1 cells were differentiated to the attached state (M0) with 12-myristate 13-acetate (PMA; Sigma) at 50 ng/ml for 6 h. The attached cells generated M2-polarized macrophages following treatment with PMA plus 20 ng/ml IL-4 and 20 ng/ml IL-13 (R&D Systems) for another 66 h. The M1 polarization medium was treated with PMA plus 10 ng/ml LPS (Sigma) and 20 ng/ml IFN-γ (R&D systems) for 66 h.

Flow cytometry analysis {#Sec8}
-----------------------

Differentiated THP-1 cells were washed with PBS three times. To detect M1 markers, the cells were incubated with CCR7-APC (MACS) monoclonal antibody for 1 h. To detect the M2 markers, the cells were incubated with primary CD163 (Santa Cruz) monoclonal antibody for 1 h. After 1 h, the cells were washed with PBS and then incubated with FITC-conjugated goat anti-mouse secondary antibody for 1 h. The samples were analyzed by flow cytometry on an FLSR II flow cytometry system (BD).

Radiosensitivity assay {#Sec9}
----------------------

In addition to IL-4 and IL-13, human CEA (300 ng/mL) (Abcam) was also added for 66 h during M2 differentiation. We collected CEA-stimulated M2 conditioned medium (CM) for 1: 1 mixture of culture of colon cancer cells. After 24 h, cancer cells were irradiated with 8 Gy then seeded in 96 well plate for 72 h. The cells were counted using a Cell Proliferation Reagent WST-1 (Roche Molecular Biochemicals, Mannheim, Germany). The analysis method was applied according to the instructions supplied by the manufacturer. Briefly, WST-1 (20μl) was added to well for 30 min the OD (450 nm) was measured for counting of cell number. No CEA-stimulated M2 CM, CEA + cancer cell-free medium, and cancer cell-free medium were also added to culture medium of colon cancer cells for comparison. OD after irradiation was compared between M2 CM and M2 CM + CEA group using paired-t test. The corresponding OD was also compared between cancer cell-free medium and cancer cell-free medium +CEA group.

Gene expression profiling {#Sec10}
-------------------------

The total RNAs were run on an Agilent RNA 6000 Nanochip (Agilent Technologies, Palo Alto, CA) using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA) to detect the RNA quality and to determine the concentration of RNA using a NanoDrop spectrophotometer (Thermo Science, Wilmington, DE). Only samples with A260/A280 ratios of 1.9 to 2.1 and RNA integrity numbers (RINs) over 7.0 were used for the subsequent cRNA amplification analysis. A total of 500 ng of RNA was used for the synthesis of the first strand cDNA and the in vitro transcription (IVT) of the cRNA using an Illumina TotalPrep RNA Amplification Kit (Ambion, Austin, TX) according to the manufacturer's directions. Briefly, a single 20-μl aliquot of RNA and reverse transcription master mix was incubated for 2 h at 42°C to synthesize the first strand cDNA. Eighty microliters of second strand master mix was added, and the solution was incubated for 2 h at 16°C to synthesize the second strand cDNA. After incubation with 7.5 μl IVT master mix for 14 h at 37°C and purification, the size distribution of the synthesized biotin-labeled cRNA was evaluated with an Agilent 2100 Bioanalyzer. Gene expression was analyzed using the Sentrix HumanHT-12 v4 Expression BeadChip (Illumina, San Diego, CA) to generate the expression profiles of more than 47,000 probes with 750 ng of labeled cRNA for each sample according to the manufacturer's protocol. After hybridization for 20 h at 58°C, washing and fixation, the HumanHT-12 Expression BeadChip was detected with Cy3-streptavidin (GE Healthcare, Little Chalfont, Buckinghamshire, UK) and quantitated using an Illumina BeadStation 500GX (Illumina, San Diego, CA). The expression intensity measures were obtained and extracted with the gene expression module version 1.9.0 of the Illumina GenomeStudio V2011.1 software (Illumina, San Diego, CA) for further bioinformatics analysis.

Microarray data analysis {#Sec11}
------------------------

All of the gene expression data were log2 transformed and exported using the Partek Report Plugin 2.16 of the Illumina GenomeStudio platform in the Partek Genomics Suite version 6.6. The gene expression levels in the samples were quantile-normalized in the Partek analysis software and subsequently analyzed for differential genetic expression profiles. The analysis of variance (ANOVA) algorithm of the Partek software was used to compare the differentially expressed genes between the CEA-stimulated and vehicle-stimulated macrophages. Changes in gene expression levels of 2- to 5-fold in the CEA-stimulated samples relative to the vehicle-stimulated controls with *p* values \< 0.05 were considered to be significant. Visualizations of heatmaps of the hierarchical clusterings and the biological interpretations from Gene Ontology (GO) Enrichment and the KEGG pathway are presented for the significant genes.

Results {#Sec12}
=======

Treatment outcomes {#Sec13}
------------------

The median follow-up time for the patients who are alive was 98.9 months (range 45--156 months). The 5-year OS, DM, and LR values were 56.2%, 49.8%, and 14.1%, respectively. DM was noted in 50 patients. Among the 38 patients who underwent CEA examinations upon DM, 26 patients (68.4%) had CEA levels \> 5 ng/mL. The 5 most common sites of DM were the lungs (16.8%), liver (14.0%), para-aortic lymph node (8.4%), carcinomatosis (6.6%), and brain (5.6%), which were noted in 18, 15, 9, 7, and 6 patients, respectively. LR was noted in 13 patients. Among 5 patients who underwent CEA examinations upon LR, 4 patients (80%) had CEA levels \> 5 ng/mL. The DM rates were 92.3% and 41.8% in the patients with and without LR (*p* = 0.001), respectively. The median time to DM was 16.4 months (range 1--86). The median time to LR was 13.7 months (range 4--87).

The univariate and multivariate analyses are presented in Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. The 5-year OS rates were 64.5% and 35.9% (*p* = 0.004) in the patients with pretreatment CEA levels of \< 10 and ≥ 10 ng/mL (Fig. [1](#Fig1){ref-type="fig"}), respectively. The DM rates were 40.6% and 73.1% (*p* = 0.024) in the patients with pretreatment CEA levels of \< 10 and ≥ 10 ng/mL (Fig. [2](#Fig2){ref-type="fig"}), respectively. The LR rates were 6.6% and 33.9% (*p* = 0.002) in the patients with pretreatment CEA levels of \< 10 and ≥ 10 ng/mL (Fig. [3](#Fig3){ref-type="fig"}), respectively. The multivariate analyses revealed that pretreatment CEA levels of \< 10 and ≥ 10 ng/mL were the only independent predictive factors for OS (*p* = 0.005; HR: 2.229; 95% CI 1.272--3.906), DM (*p* = 0.026; HR: 1.923; 95% CI 1.080--3.423), and LR (*p* = 0.004; HR: 5.340; 95% CI 1.682--16.955).Table 2Univariate and multivariate analysis of overall survival (OS)Parameters5-year OS*p* valueHazard ratio (95% CI)*p* valueAge0.7590.513  \< 5756.3%reference ≥ 5756.2%---Stage0.4340.513 II62.9%reference III54.5%---T stage0.1210.204 T2100%reference T360.2%--- T447.5%---N stage0.7360.798 062.9%reference 155.7%--- 252.0%---APR0.4310.459 No56.7%reference Yes55.7%---Anal verge (cm)0.1960.169 ≤555.9%reference 6--1063.5%---  \> 1036.4%---Pretreatment CEA level0.0040.005  \< 10 ng/mL64.5%reference ≥ 10 ng/mL35.9%2.229 (1.272--3.906)*Abbreviations*: CI = confidence interval; CEA = Carcinoembryonic antigenTable 3Univariate and multivariate analysis of distant metastasis (DM)Parameters5-year DM*p* valueHazard ratio (95% CI)*p* valueAge0.4590.694  \< 5753.2%reference ≥ 5746.2%---Stage0.0650.100 II35.5%reference III52.8%---T stage0.2000.286 T20%reference T344.6%--- T459.3%---N stage0.0860.149 035.5%reference 149.0%--- 262.0%---APR0.6430.667 No47.3%reference Yes53.7%---Anal verge (cm)0.0710.066 ≤553.3%reference 6--1033.0%---  \> 1084.1%---Pretreatment CEA level0.0240.026  \< 10 ng/mL40.6%reference ≥ 10 ng/mL73.1%1.923 (1.080--3.423)Table 4Univariate and multivariate analysis of local recurrence (LR)Parameters5-year LR*p* valueHazard ratio (95% CI)*p* valueAge0.4120.755  \< 5718.8%reference ≥ 579.0%---Stage0.7230.998 II14.1%reference III14.1%---T stage0.5840.806 T20%reference T312.2%--- T417.7%---N stage0.9170.898 014.1%reference 113.5%--- 214.9%---APR0.1210.134 No9.9%reference Yes20.2%---Anal verge (cm)0.5230.341 ≤514.7%reference 6--1011.1%---  \> 1020.5%---Pretreatment CEA level0.0020.004  \< 10 ng/mL6.6%reference ≥ 10 ng/mL33.9%5.340 (1.682--16.955)Fig. 1Lower overall survival rate in the patients with CEA levels ^3^ 10 ng/mLFig. 2Higher distant metastasis rate in the patients with CEA levels ^3^ 10 ng/mLFig. 3Higher local recurrence rate in the patients with CEA levels ^3^ 10 ng/mL

CEA stimulated M0 cells toward M2 differentiation {#Sec14}
-------------------------------------------------

Different morphologies were noted between the M0, M1, and M2 cells (Fig. [4](#Fig4){ref-type="fig"}). We used CCR7 and CD163 as markers of M1 and M2 cells, respectively. We noted a dose-response relationship of CEA with M2 differentiation (Fig. [5](#Fig5){ref-type="fig"}). We tested the CEA levels of the supernatants from different colon cancer cell lines (SW48, SW620, DLD-1, HCT116, LS1034, LS174T, and Caco2). We noted 18.392 ng/mL in LS1034 cells and 8.357 ng/mL in LS174T. Levels lower than 1 ng/mL were noted in the other cell lines (Table [5](#Tab5){ref-type="table"}). Hence, we used the LS1034 cells for radiosensitivity testing.Fig. 4Morphologies of the M0, M1 and M2 macrophages with and without CEA stimulationFig. 5M1 (CCR7) and M2 (CD163) expression after CEA stimulation of M0 cellsTable 5CEA concentration in supernatant of different colon cancer cell linesCellsCEA (ng/ml)mediumCEA (ng/ml)SW480.367L-150.087SW6200.266L-150.087DLD-10.557RPMI0.51LS103418.392RPMI0.51HCT1160.3795A0.357LS174T8.357MEM0.334caco20.692DMEM0.332Determined by radioimmunoassay (RIA)

Gene expression in CEA-stimulated macrophages {#Sec15}
---------------------------------------------

In the CEA-stimulated M0 macrophages (Fig. [6](#Fig6){ref-type="fig"} and Table [6](#Tab6){ref-type="table"}), four mRNAs that exhibited at least 5-fold down-regulation compared with the vehicle-stimulated M0 cells were noted. Five mRNAs, including MMP12, GDF15, and JAG1, exhibited at least 5-fold up-regulation. In the CEA-stimulated M1 macrophages (Fig. [7](#Fig7){ref-type="fig"} and Table [7](#Tab7){ref-type="table"}), three mRNAs were at least 2-fold down-regulated compared with the vehicle-stimulated M1 cells. Six mRNAs exhibited at least 2-fold up-regulation. In the CEA-stimulated M2 macrophages, 15 mRNAs exhibited at least 2-fold down-regulation compared with the non-stimulated M2 cells. Twenty-four mRNAs exhibited at least 2-fold up-regulation. The GADD45G mRNA achieved a 4-fold up-regulation of expression. GADD45G is a stress response gene to radiotherapy.Fig. 6Hierarchical clustering of the up- and down-regulated genes (5-fold) after CEA (2 μg/mL) stimulation of M0 macrophagesTable 6Genes of up and down regulation (5-fold) after CEA stimulation in M0 macrophageSymbol*p*-value (M0 + CEA vs. M0)Log fold (M0 + CEA vs. M0)Fold-Change (M0 + CEA vs. M0)MMP120.02579230.7016135.03052FCGR1A0.0422142−0.70421−5.06069PNCK0.0398482−0.70525−5.07281PGA50.0297503−0.7423−5.52462HGC6.30.0373702−0.78718−6.12611GDF150.008401810.7856266.10416JAG10.04375050.7201475.24985SPINK10.003465191.1426413.888LOC645464^a^0.01305190.7398745.49381MMP12 = Matrix metalloproteinase-12FCGR1A = High affinity immunoglobulin gamma Fc receptor IPNCK = Pregnancy Up-Regulated Nonubiquitous CaM Kinase*PGA5 = pepsinogen 5*HGC6.3 = Human hypothetical LOC100128124GDF15 = Growth/differentiation factor 15JAG1 = Jagged1SPINK1 = serine protease inhibitor Kazal-type 1^a^This record has been withdrawn by NCBI because the model on which it was based was not predicted in a later annotationFig. 7Hierarchical clustering of the up- and down-regulated genes (2-fold) after CEA (2 μg/mL) stimulation of M1 macrophagesTable 7Genes of up and down regulation (2-fold) after CEA stimulation in M1 macrophageSymbol*p*-value (M1 + CEA vs. M0)Log fold (M1 + CEA vs. M0)Fold-change (M1 + CEA vs. M0)KRTAP4--50.0159843−0.30188−2.00392SLFNL10.0316286−0.35666−2.27333LOC729379^a^0.000549518−0.3691−2.3394CT47B10.0002594430.4394422.75069XLKD10.005634310.3311382.14357FAT20.00944461−0.3035−2.01141CLCA30.007675310.3411142.19338MFRP0.00689281−0.40706−2.55305OR8K30.0121585−0.39214−2.46683KRTAP4--5 = keratin associated protein 4--5SLFNL1 = schlafen like 1LOC729379CT47B1 = Cancer/Testis Antigen Family 47, Member B1XLKD1 = extracellular link domain containing 1FAT2 = FAT atypical cadherin 2CLCA3 = Chloride channel accessory 3,MFRP = membrane frizzled-related proteinOR8K3 = olfactory receptor family 8 subfamily K member 3^a^This record has been withdrawn by NCBI because the model on which it was based was not predicted in a later annotation

The conditioned media from CEA-stimulated M2 macrophages enhanced radioresistance {#Sec16}
---------------------------------------------------------------------------------

The conditioned media from M2 macrophages or medium only was applied to the LS1034, SW620, LS180 cells prior to irradiation. We compared the OD for cell proliferation between the CEA-stimulated and vehicle-stimulated cells after irradiation. We found a higher OD in the CEA-stimulated group with M2 conditioned medium but not medium only group (Fig. [8](#Fig8){ref-type="fig"}).Fig. 8CEA (320 ng/mL) enhanced the radioresistance of (**a**) LS180, (**b**) SW620, and (**c**) LS1034 cells cultured with M2 conditioned medium. However, CEA did not change radiosensitivity in cancer cells without M2 conditioned medium. Each experimental group included triplicated studies

Discussion {#Sec17}
==========

Regardless of an early report of preoperative CEA in recurrent colorectal cancer \[[@CR10]\], the role of CEA in the prognoses may be dependent on the disease site (i.e., colon or rectal cancer), whether radiotherapy is applied, the end points examined (i.e., OS, DM, and LR), and the time at which the CEA level is measured. Therefore, CEA is involved in cancer progression and recurrence (following surgery or radiotherapy) in some studies, especially in the era of the established roles of neoadjuvant and adjuvant radiotherapies. In rectal cancer, the role of the pretreatment CEA level has been well studied in terms of neoadjuvant therapy with the endpoints of pathologically complete responses \[[@CR11]--[@CR17]\] and OS \[[@CR18]\]. Normalization of the CEA level after neoadjuvant therapy is also a significant factor in pathologically complete responses \[[@CR19]\] and prognoses \[[@CR14], [@CR20], [@CR21]\].

There is only one study that has examined the prognostic role of preoperative CEA levels in Dukes' B and C patients who have undergone PORT for rectal cancer \[[@CR22]\]. The authors of this study found no significant role of CEA in LR. A second study \[[@CR23]\] included stage II and III preoperative and post-operative CCRT patients. The 5-year OS, DM, and LR rates were 49.4%, 14.9%, and 66.0%, respectively. These authors noted that a CEA level \> 3 ng/mL affected the OS and LR but not the DM based on univariate analysis. The CEA level was treated as a continuous variable in a multivariate analysis and was found to be an independent factor for OS.

In the present study, we included only PORT and not neoadjuvant patients. We studied not only the OS but also the LR and DM and noted significant roles of CEA in all of the end points. The preoperative CEA level may serve as a marker of occult metastasis and radioresistance to PORT in rectal cancer. This study also confirmed the results of our previous study that investigated the role of pretreatment CEA levels in the LRs, DMs, and OSs of patients undergoing definitive radiotherapy for cervical cancer \[[@CR2], [@CR24]\]. We also found that LR usually preceded DM, and a higher DM rate was noted in patients with LR than in those without LR. We observed an early separation of the Kaplan-Meier curves for LR (at approximately \< 6 months; Fig. [3](#Fig3){ref-type="fig"}) between the patients with high and low CEA levels but did not observe this early separation for OS (the separation occurred at approximately 2 years; Fig. [1](#Fig1){ref-type="fig"}) or DM (the separation occurred at approximately 1 year; Fig. [2](#Fig2){ref-type="fig"}). CEA first involves LR, which increases the DM and thus affects survival. Therefore, the reviewed literature and our results support the role of CEA in LR. In other words, CEA may be a marker of radioresistance. For this reason, we attempted to investigate the mechanism by which CEA affects radioresistance in an in vitro study.

Macrophages are the major immune cells in cancer microenvironments \[[@CR25]\]. Monocytes in cancer tissues can differentiate into M0 macrophages. If M0 cells are stimulated with IFN-γ, LPS, and TNF-α, they differentiate into M1 macrophages that exhibit pro-inflammatory functions. If M0 cells are stimulated with IL-4, IL-10, and the Toll-like receptor, they differentiate into M2 macrophages that exhibit anti-inflammatory functions that improve wound-healing, angiogenesis, and remodeling. However, cancer cells can co-operate with M2 macrophages to promote proliferation, migration, invasion, angiogenesis and metastasis. For example, M2 macrophages secrete EGF, which promotes cancer cell progression \[[@CR26]\].

The interaction of CEA and macrophages has been noted in some studies \[[@CR7], [@CR8]\]. Cui et al. noted a positive correlation of M2 cells but not M1 cells with the preoperative CEA level in colorectal cancer patients with liver metastases \[[@CR27]\]. Therefore, we suggest that CEA can stimulate macrophages toward M2 differentiation and subsequently release radioresistant molecules that affect cancer cells. The interesting finding of the present study is that CEA stimulates GADD45G mRNA expression by M2 macrophages. GADD45G is a DNA damage response gene \[[@CR28]\] that is associated with radiation. GADD45G also induces hematopoietic stem cell differentiation \[[@CR29]\]. Furthermore, GADD45G increases TNF-α and IL-6 production in LPS-stimulated THP-1 cells \[[@CR30]\].

We noted the expressions of some genes in the CEA-stimulated M0 macrophages. Some of these genes may be involved in macrophage-mediated cancer progression. MMP12 can enhance the progression of nasopharyngeal carcinomas through the heterogeneous nuclear ribonucleoprotein (hnRNP) K \[[@CR31]\]. Interestingly, CEA increases IL-6 and TNF-α expressions through hnRNP M4 \[[@CR8]\]. Additional mechanisms are worth investigating. Growth differentiation factor 15 (GDF15) is a superfamily of TGF-β that is expressed by M2 macrophages. Human jagged 1 (JAG1) is a receptor of the Notch-1 ligand, and JAG1 expression is under the control of hematopoietic growth factors \[[@CR32]\]. In the present study, CEA was found to increase JAG1 expression. Because JAG1 and Notch-1 are poor prognostic factors in several cancers \[[@CR33]--[@CR35]\], it is reasonable to propose that the role of CEA in cancer progression is mediated through JAG1 and Notch-1 expressions in M0 cells.

There are some limitations of this study. A high DM rate was noted in the present study. An inadequate number of lymph node examinations was noted in our hospital, and this likely affected the prognoses \[[@CR36]\]. Hence, the stages of the patients included in the present study might have been underestimated, and occult metastases might have appeared. These occult metastases resulted in the DM rate. The sample size was limited because most of the patients referred to our department underwent preoperative radiotherapy, and not all pT3--4 and pN1--2 patients were referred for PORT. The data presented is sufficient to generate the hypothesis rather than being robust enough to prove the point. Other causes for radioresistance are not accounted for. More direct studies of the stromal cells are required to prove the issue.

Conclusion {#Sec18}
==========

Based on our results and the literature, CEA may stimulate M2 but not M1 differentiation. CEA causes radioresistance in the presence of M2 macrophages. Pretreatment CEA levels ≥ 10 ng/mL are a significant risk factor for OS, DM, and LR following PORT for rectal cancer. More comprehensive examinations prior to surgery and intensive adjuvant therapy are suggested for patients with CEA levels ≥10 ng/mL. Further translational studies of these mechanisms are needed.
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